Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antisense drug therapies - GlaxoSmithKline/Ionis Pharmaceuticals/ProQR Therapeutics

Drug Profile

Research programme: antisense drug therapies - GlaxoSmithKline/Ionis Pharmaceuticals/ProQR Therapeutics

Alternative Names: ISIS-AATRx; ISIS-GSK5Rx; ISIS-RHO-2.5Rx; QR 1123

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Class Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action Alpha 1 adrenergic receptor modulators; Alpha 1 antitrypsin modulators; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alpha 1-antitrypsin deficiency; Blindness; Eye disorders; Infections; Retinitis pigmentosa

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA
  • 29 Oct 2018 ProQR Therapeutics in-licenses QR 1123 from Ionis Pharmaceuticals
  • 29 Oct 2018 ProQR Therapeutics plans to files an IND application with the US FDA for Retinitis pigmentosa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top